| Healthcare Review: Derma Sciences, Dynavax Technologies, Curis, Lexicon Pharmaceuticals, Emergent BioSolutions |
 |
 |
| By Staff and Wire Reports |
| Thursday, 07 August 2014 14:50 |
 U.S. stocks edged lower in early afternoon trading as investors assessed the latest company earnings and the outlook for the economy.
Investors are still troubled by the potential for escalating tensions between Russia and the West over Ukraine. The yield on the 10-year Treasury note fell to its lowest level of the year. The Standard & Poor's 500 index fell three points, or 0.2 percent, to 1,917 as of 2:03 p.m. Eastern time. The Dow Jones industrial average fell 32 points, or 0.2 percent, to 16,410. The Nasdaq composite was unchanged at 4,555.
Derma Sciences ($DSCI) Q2 results: Revenues: $20.9M (+15.5%); Gross Profit: $7.8M (+12.2%); Operating Expenses: $17.0M (+20.6%); Operating Loss: ($9.2M) (-23.8%); Net Loss: ($8.7M) (-18.3%); Loss Per Share: ($0.34) (+20.9%); Quick Assets: $88.6M (+302.7%). Dynavax Technologies ($DVAX) Q2 results: Revenues: $3.0M (-10.1%); Operating Expenses: $27.9M (+36.8%); Operating Loss: ($24.9M) (-46.5%); Net Loss: ($24.8M) (-44.2%); Loss Per Share: ($0.09) (unch); Quick Assets: $154.3M (-18.5%). Curis ($CRIS) Q2 results: Revenues: $1.8M (+126.5%); Operating Expenses: $6.3M (+3.9%); Operating Loss: ($1.5M) (-118.7%); Net Loss: ($1.9M) (-46.5%); Loss Per Share: ($0.02) (unch); Quick Assets: $59.0M (-14.4%). Lexicon Pharmaceuticals ($LXRX) Q2 results: Revenues: $676K (+215.9%); Operating Expenses: $26.8M (-7.1%); Operating Loss: ($26.1M) (+8.8%); Net Loss: ($26.0M) (+10.5%); Loss Per Share: ($0.05) (+16.7%); Quick Assets: $79.0M (-38.8%). Emergent BioSolutions (NYSE:EBS) submits a BLA to the FDA for Anthrax Immune Globulin IV (Human) [AIGIV] as part of its contract with the Biomedical Advanced Research and Development Authority (BARDA). The product is an IV therapeutic treatment for anthrax inhalation. AIGIV is a sterile solution of purified human immune globulin (IgG) that contains polyclonal antibodies that target anthrax toxins of Bacillus anthracis. "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites            |
Newsletter
